Previous close | 3.6700 |
Open | 3.6700 |
Bid | 3.6700 x 800 |
Ask | 3.6800 x 1800 |
Day's range | 3.6700 - 3.6800 |
52-week range | 2.0790 - 3.8100 |
Volume | |
Avg. volume | 44,622 |
Market cap | 116.378M |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.6600 |
Earnings date | 11 Dec 2023 - 12 Dec 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.34 |
BEIJING, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), a
BEIJING, May 23, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated May 17, 2023, indicating that for the
BEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter (“Compliance Notice”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), dated Jan